CCA
MRNA icon

Column Capital Advisors’s Moderna MRNA Stock Holding History

Column Capital Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$117K Hold
117,112
– – 0.02% 201
2023
Q2 		$117K Hold
117,112
– – 0.02% 197
2023
Q1 		$117K Sell
117,112
-9
-0% -$1.49K 0.02% 200
2022
Q4 		$119K Buy
+117,121
New +$19.2M 0.02% 183
2022
Q1 		– Sell
-1
Closed – – 780
2021
Q4 		$0 Buy
+1
New +$292 ﹤0.01% 813
2020
Q1 		– Sell
-162
Closed -$3K – 765
2019
Q4 		$3K Buy
+162
New +$2.87K ﹤0.01% 582

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return